PFM Health Sciences’s Vertex Pharmaceuticals VRTX Stock Holding History

PFM Health Sciences’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-126,989	Closed	-$61.6M	–	77
2025 Q1	$61.6M	Hold	126,989	–	–	4.47%	7
2024 Q4	$51.1M	Sell	126,989 -21,863	-15%	-$10.1M	3.17%	7
2024 Q3	$69.2M	Hold	148,852	–	–	3.92%	5
2024 Q2	$69.8M	Hold	148,852	–	–	3.45%	6
2024 Q1	$62.2M	Hold	148,852	–	–	2.93%	6
2023 Q4	$60.6M	Buy	+148,852	New	+$55M	3.63%	5
2021 Q2	–	Sell	-46,889	Closed	-$10.1M	–	98
2021 Q1	$10.1M	Buy	+46,889	New	+$10.3M	0.31%	63
2020 Q3	–	Sell	-59,035	Closed	-$17.1M	–	95
2020 Q2	$17.1M	Sell	59,035 -36,447	-38%	-$9.88M	0.89%	42
2020 Q1	$22.7M	Buy	95,482 +38,560	+68%	+$8.85M	1.87%	22
2019 Q4	$12.5M	Buy	+56,922	New	+$11.5M	0.59%	43
2016 Q3	–	Sell	-135,487	Closed	-$11.7M	–	106
2016 Q2	$11.7M	Buy	+135,487	New	+$11.7M	0.35%	68

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PFM Health Sciences's VRTX Position: Q2 2025 in Review

PFM Health Sciences sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 126,989 shares — an estimated $61.6M sold.

PFM Health Sciences first reported a position in VRTX in Q2 2016 and held it in 11 quarters. The position peaked at $69.8M in Q2 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

PFM Health Sciences reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
PFM Health Sciences sold 126,989 Vertex Pharmaceuticals shares in Q2 2025, an estimated $61.6M.
PFM Health Sciences first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 11 quarters.
PFM Health Sciences's Vertex Pharmaceuticals position peaked at $69.8M in Q2 2024.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.